Laurane Mackels

Dr. Laurane Mackels

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2022 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Open access
GFGemma Fisher
Gemma Fisher
LMLaurane Mackels
Laurane Mackels
TMTheodora Markati
Theodora Markati
ASAnna Sarkozy
Anna Sarkozy
JOJulien Ochala
Julien Ochala
LSLaurent SERVAIS
Laurent SERVAIS
: Nemaline myopathies (NM) represent a group of clinically and genetically heterogeneous congenital muscle disorders with the common denominator of nemaline rods on muscle biopsy. NEB and ACTA1 are...

Verified
Journal Article
Open access
PDF file
LMLaurane Mackels
Laurane Mackels
XLXincheng Liu
Xincheng Liu
GBGisèle Bonne
Gisèle Bonne
LSLaurent SERVAIS
Laurent SERVAIS
Human TOR1AIP1 encodes LAP1, a nuclear envelope protein expressed in most human tissues, which has been linked to various biological processes and human diseases. The clinical spectrum of diseases related to mutations in TOR1AIP1 is broad, including muscular dystrophy, congenital myasthenic syndrome, cardiomyopathy, and multisystemic disease with or without progeroid features. Although rare, these recessively inherited disorders often lead to early death or considerable functional impairment. Developing a better understanding of the roles of LAP1 and mutant TOR1AIP1-associated phenotypes is paramount to allow therapeutic development. To facilitate further studies, this review provides an overview of the known interactions of LAP1 and summarizes the evidence for the function of this protein in human health. We then review the mutations in the TOR1AIP1 gene and the clinical and pathological characteristics of subjects with these mutations. Lastly, we discuss challenges to be addressed in the future.

Verified
Journal Article
Open access
PDF file
LMLaurane Mackels
Laurane Mackels
VMVirginie MARIOT
Virginie MARIOT
LBLaura Buscemi
Laura Buscemi
LSLaurent SERVAIS
Laurent SERVAIS
Julie DumonceauxJulie Dumonceaux
Julie Dumonceaux
Clinical trials with treatments inhibiting myostatin pathways to increase muscle mass are currently ongoing in spinal muscular atrophy. Given evidence of potential myostatin pathway downregulation in Spinal Muscular Atrophy (SMA), restoring sufficient myostatin levels using disease-modifying treatments (DMTs) might arguably be necessary prior to considering myostatin inhibitors as an add-on treatment. This retrospective study assessed pre-treatment myostatin and follistatin levels’ correlation with disease severity and explored their alteration by disease-modifying treatment in SMA. We retrospectively collected clinical characteristics, motor scores, and mysotatin and follistatin levels between 2018 and 2020 in 25 Belgian patients with SMA (SMA1 (n = 13), SMA2 (n = 6), SMA 3 (n = 6)) and treated by nusinersen. Data were collected prior to treatment and after 2, 6, 10, 18, and 30 months of treatment. Myostatin levels correlated with patients’ age, weight, SMA type, and motor function before treatment initiation. After treatment, we observed correlations between myostatin levels and some motor function scores (i.e., MFM32, HFMSE, 6MWT), but no major effect of nusinersen on myostatin or follistatin levels over time. In conclusion, further research is needed to determine if DMTs can impact myostatin and follistatin levels in SMA, and how this could potentially influence patient selection for ongoing myostatin inhibitor trials.

27 January 2022 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
LMLaurane Mackels
Laurane Mackels
MMMartin Moïse
Martin Moïse
FDFrédérique Depierreux
Frédérique Depierreux

25 November 2024 in Tremor and Other Hyperkinetic Movements
Verified
Journal Article
Open access
LMLaurane Mackels
Laurane Mackels
DADavid Aktan
David Aktan
FDFrédérique Depierreux
Frédérique Depierreux
While levodopa may benefit some patients with monogenic Parkinson’s Disease and parkinsonism, others may exhibit aberrant responses earlier after exposure. Reporting treatment responses in rare genetic parkinsonism will help tailor therapeutic approaches to specific patients subpopulations. We report the therapeutic response in a patient with RAB39B X-linked parkinsonism, who exhibited motor and non-motor complications within a few months of Levodopa. Severe and debilitating Levodopa-induced complications can occur very early in the treatment course of X-linked parkinsonism, highlighting the need for an individualized therapeutic approach and follow-up in rare parkinsonian syndromes.